Charlotte Hubbert

Charlotte Hubbert is an Associate and Kauffman Fellow with Accelerator Corporation, a Seattle-based privately-held biotechnology investment and development company that is building the next generation of biotechnology companies. She has twelve years of life sciences experience, with proven performance in internationally recognized publications including Science and Nature. Charlotte holds a Ph.D.from Duke University and recently finished post-doctoral training at the University of Washington Institute for Stem Cell and Regenerative Medicine. Prior to science, she was an impoverished musician and trouble-making rockstar.

Recent posts

Chicken Little is History, Now It’s Time for Old School VC
“Biotech is Broken!” “Pharmaceuticals Out of Balance!” “Venture Capital abandoning Biotech Sector!”
Lately articles on the state of biotech scream out like spinning headlines on the MovieTone News Reels from seventy... Read more »
From Academics to Biotech: A Journey to the Supposed “Dark Side”
If you had told me last year that today I would be running the offices of Accelerator Corporation—at least for one morning while everyone is out of town—I would have... Read more »

Page 1 of 1

Underwriters and Partners

Xpertise: Watch + Learn

Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX

Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX

Xconomy Insight · Webinar
The New Era of Emerging Therapies Webinar Series
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.